Introduction {#Sec1}
============

The spread of extended-spectrum beta-lactamase-producing *Enterobacteriaceae* (ESBL-E) is a major issue in ICU patients. Whether ESBL-E carriage and infection impact the outcome and the use of carbapenems in this population remains scarcely evaluated.

Objectives {#Sec2}
==========

We investigated the effects of ESBL-E carriage and infection on carbapenem consumption, ICU length of stay (LOS), and adjusted probability of death at day-28 (D28) in a multicenter cohort of critically ill patients.

Methods {#Sec3}
=======

Adult patients admitted between January 1996 and December 2013 in 17 French ICUs contributing to the OUTCOMEREA prospective database were included. Screening for ESBL-E carriage was performed at ICU admission and weekly thereafter. a cause-specific hazard model was built to assess the impact of carriage with and without ICU-acquired infection due to ESBL-E on the likelihood of death or ICU discharge at D28.

Results {#Sec4}
=======

Among the 16,734 included patients, 594 (3.5%) were colonized with ESBL-E during their ICU stay (imported carriage, 52.2%). a total of 118 ESBL-E infections occurred in 98 carriers (16.4%). Both ESBL-E infections and ESBL-E carriage without infection increased the use of carbapenems during the ICU stay when compared to non-carriage (627, 241 and 69 treatment days for 1,000 patient-days, respectively, p \< 0.001 for all comparisons). The ICU LOS was longer in carriers than in non-carriers (median \[IQR\], 13 \[6-26\] vs 5 \[3-9\] days, p \< 0.01) but similar in carriers with and without ESBL-E infection (13 \[6-29\] vs 13 \[6-26\] days, p = 0.52). Crude mortality rates at D28 were higher in carriers than in non-carriers (19.7% vs 15.6%, p \< 0.01), and further differed when comparing carriers with ESBL-E infections and uninfected carriers (30.6% vs 17.5%, p \< 0.01). After adjustment on baseline (chronic diseases, type of admission, and SAPS II and organ failures at ICU admission) and time-dependent (SOFA score at the time of ESBL-E acquisition, and end-of-life decisions) variables, ESBL-E infections increased the risk of death at D28 \[adjusted cause-specific hazard ratio (aCSHR) 1.825, 95% confidence interval (95%CI) 1.235-2.699, p = 0.003\] and the ICU LOS (aCSHR 0.563, 95%CI 0.432-0.733, p \< 0.001). ESBL-E carriage without infection prolonged the ICU stay (aCSHR 0.623, 95%CI 0.553-0.702, p \< 0.001), but had no effect on D28 mortality (aCSHR 0.906, 95%CI 0.722-1.136, p = 0.4). When analyzed separately, the effects of carriage and infection did not differ between ESBL-producing *Escherichia coli* (48.7% of carriage isolates) and other ESBL-E.

Conclusions {#Sec5}
===========

In this large cohort of critically ill patients, ESBL-E infections increased carbapenem consumption, ICU LOS, and D28 mortality. Less than one fifth of carriers developed an ESBL-E infection; however, even ESBL-E carriage without infection increased carbapenem exposure and delayed discharge, thereby amplifying both the selective pressure and the colonization pressure in the ICU.
